Medical Oncology

, Volume 29, Issue 4, pp 2710–2715 | Cite as

Overexpression of the HIF hydroxylase PHD3 is a favorable prognosticator for gastric cancer

  • Changlei Su
  • Kejin Huang
  • Lingyu Sun
  • Dongdong Yang
  • Hongqun Zheng
  • Changlu Gao
  • Jinxue Tong
  • Qifan Zhang
Original Paper
First Online:
Received:
Accepted:
  • 265 Downloads

Abstract

Hypoxia-induced factors (HIFs) play a central role in the adaptive mechanisms of cancer cells to survive under conditions of hypoxia. HIFs are regulated by prolyl hydroxylases (PHDs) among which PHD3 is implicated as a tumor suppressor. We aimed to correlate PHD3 expression with clinicopathologic parameters and to evaluate its prognostic significance in gastric cancer. The 101 tissue samples were collected from 83 resected stages I–IV gastric cancer patients, which were grouped as non-cancerous mucosa (n = 18) and primary carcinoma (n = 83). PHD3 expression was evaluated by immunohistochemistry. We adopted Pearson chi-square test, univariate analysis, multivariate analysis and Kaplan–Meier method. The positive frequency of PHD3 in cancer cells was 42.2%, whereas non-cancerous mucosa had no detectable PHD3. The expression of PHD3 increased significantly from non-cancerous mucosa to cancer. A significant difference was observed between PHD3 expression and tumor differentiation (P = 0.007). The overexpression of PHD3 was associated with well differentiation. In univariate analyses, American Joint Committee on Cancer (AJCC) stage (P < 0.0001), pT classification (P < 0.0001), pN classification (P < 0.0001), differentiation (P = 0.0121), peritoneal metastasis (P = 0.0006) and gross features (P = 0.0104) were significantly associated with survival except PHD3 (P = 0.2228) (Table 3). In multivariate analysis, AJCC stage was prognostically independent [hazard ratio (HR), 3.078; 95% confidence interval (CI), 2.228–4.252; P < 0.0001]. Overexpression of PHD3 is a favorable prognosticator for gastric cancer. AJCC stage is an independent prognostic factor of gastric cancer.

Keywords

Gastric cancer Differentiation Prognosis PHD3 Apoptosis 
This is a preview of subscription content, log in to check access.

Notes

Conflict of interest

None.

References

  1. 1.
    Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.PubMedCrossRefGoogle Scholar
  2. 2.
    Catalano V, Labianca R, Beretta GD, Gatta G, de Braud F, Van Cutsem E. Gastric cancer. Crit Rev Oncol Hematol. 2009;71:127–64.PubMedCrossRefGoogle Scholar
  3. 3.
    Kato Y, Yashiro M, Fuyuhiro Y, Kashiwagi S, Matsuoka J, Hirakawa T, Noda S, Aomatsu N, Hasegawa T, Matsuzaki T, Sawada T, Ohira M, Hirakawa K. Effects of acute and chronic hypoxia on the radiosensitivity of gastric and esophageal cancer cells. Anticancer Res. 2011;31(10):3369–75.PubMedGoogle Scholar
  4. 4.
    Osinsky S, Bubnovskaya L, Ganusevich I, Kovelskaya A, Gumenyuk L, Olijnichenko G, Merentsev S. Hypoxia, tumour-associated macrophages, microvessel density, VEGF and matrix metalloproteinases in human gastric cancer: interaction and impact on survival. Clin Transl Oncol. 2011;13(2):133–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Harris AL. Hypoxia–a key regulatory factor in tumour growth. Nat Rev Cancer. 2002;2(1):38–47.PubMedCrossRefGoogle Scholar
  6. 6.
    Andersen S, Donnem T, Stenvold H, Al-Saad S, Al-Shibli K, Busund LT, Bremnes RM. Overexpression of the HIF Hydroxylases PHD1, PHD2, PHD3 and FIH are individually and collectively unfavorable prognosticators for NSCLC survival. PLoS One. 2011;6(8):e23847.PubMedCrossRefGoogle Scholar
  7. 7.
    Zhou J, Li K, Gu Y, Feng B, Ren G, Zhang L, Wang Y, Nie Y, Fan D. Transcriptional up-regulation of RhoE by hypoxia-inducible factor (HIF)-1 promotes epithelial to mesenchymal transition of gastric cancer cells during hypoxia. Biochem Biophys Res Commun. 2011;415(2):348–54.PubMedCrossRefGoogle Scholar
  8. 8.
    Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene. 2010;29(5):625–34. doi: 10.1038/onc.2009.441.PubMedCrossRefGoogle Scholar
  9. 9.
    Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O’Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, Tian YM, Masson N, Hamilton DL, Jaakkola P, Barstead R, Hodgkin J, Maxwell PH, Pugh CW, Schofield CJ, Ratcliffe PJ. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell. 2001;107(1):43–54.PubMedCrossRefGoogle Scholar
  10. 10.
    Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, Kriegsheim Av, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, Ratcliffe PJ. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001;292:468–72. doi: 10.1126/science.1059796;1059796.
  11. 11.
    Spinella F, Rosanò L, Duca MD, Castro VD, Nicotra MR, Natali PG, Bagnato A. Endothelin-1 inhibits prolyl hydroxylase domain 2 to activate hypoxia-inducible factor-1α in melanoma cells. PLoS One. 2010;5(6):e11241.PubMedCrossRefGoogle Scholar
  12. 12.
    Metzen E, Ratcliffe PJ. HIF hydroxylation and cellular oxygen sensing. Biol Chem. 2004;385(3–4):223–30.PubMedGoogle Scholar
  13. 13.
    Appelhoff RJ, Tian YM, Raval RR, Turley H, Harris AL, Pugh CW, Ratcliffe PJ, Gleadle JM. Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem. 2004; 279(37):38458-65 [Epub 7 Jul 2004].Google Scholar
  14. 14.
    Peurala E, Koivunen P, Bloigu R, Haapasaari KM, Jukkola-Vuorinen A. Expressions of individual PHDs associate with good prognostic factors and increased proliferation in breast cancer patients. Breast Cancer Res Treat. 2011;. doi: 10.1007/s10549-011-1750-5.PubMedGoogle Scholar
  15. 15.
    Su Y, Loos M, Giese N, Hines OJ, Diebold I, Görlach A, Metzen E, Pastorekova S, Friess H, Büchler P. PHD3 regulates differentiation, tumour growth and angiogenesis in pancreatic cancer. Br J Cancer. 2010;103(10):1571–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Xue J, Li XB, Jiao S, Wei Y, Wu GH, Fang J. Prolyl hydroxylase-3 is down-regulated in colorectal cancer cells and inhibits IKK-independent of hydroxylase activity. Gastroenterology. 2010;138:606–15.PubMedCrossRefGoogle Scholar
  17. 17.
    Berra E, Ginouves A, Pouyssegur J. The hypoxia-inducible-factor hydroxylases bring fresh air into hypoxia signalling. EMBO Rep. 2006;7:41–5.PubMedCrossRefGoogle Scholar
  18. 18.
    Ginouves A, Ilc K, Macias N, Pouyssegur J, Berra E. PHDs overactivation during chronic hypoxia “desensitizes” HIFalpha and protects cells from necrosis. Proc Natl Acad Sci USA. 2008;105:4745–50.PubMedCrossRefGoogle Scholar
  19. 19.
    del Peso L, Castellanos MC, Temes E, Martin-Puig S, Cuevas Y, Olmos G, Landazuri MO. The von Hippel Lindau/hypoxia-inducible factor (HIF) pathway regulates the transcription of the HIF-proline hydroxylase genes in response to low oxygen. J Biol Chem. 2003;278:48690–5.PubMedCrossRefGoogle Scholar
  20. 20.
    Pescador N, Cuevas Y, Naranjo S, Alcaide M, Villar D, Landázuri MO, Peso LD. Identification of a functional hypoxia-responsive element that regulates the expression of the egl nine homologue 3 (egln3/phd3) gene. Biochem J. 2005;390(Pt 1):189–97.PubMedGoogle Scholar
  21. 21.
    Stiehl DP, Wirthner R, Koditz J, Spielmann P, Camenisch G, Wenger RH. Increased prolyl 4-hydroxylase domain proteins compensate for decreased oxygen levels. Evidence for an autoregulatory oxygen-sensing system. J Biol Chem. 2006;281:23482–91.PubMedCrossRefGoogle Scholar
  22. 22.
    Chen SF, Zhang J, Li XB, Luo XY, Fang J, Chen HQ. The expression of prolyl hydroxylase domain enzymes are up-regulated and negatively correlated with Bcl-2 in non-small cell lung cancer. Mol Cell Biochem. 2011;358:257–63.PubMedCrossRefGoogle Scholar
  23. 23.
    Fu J, Menzies K, Freeman RS, Taubman MB. EGLN3 prolyl hydroxylase regulates skeletal muscle differentiation and myogenin protein stability. J Biol Chem. 2007;282:12410–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Tennant DA, Gottlieb E. HIF prolyl hydroxylase-3 mediates alpha-ketoglutarate-induced apoptosis and tumor suppression. J Mol Med. 2010;88:839–49.PubMedCrossRefGoogle Scholar
  25. 25.
    Liu Y, Huo Z, Yan B, Lin X, Zhou ZN, Liang X, Zhu W, Liang D, Li L, Zhao H, Sun Y, Chen YH. Prolyl hydroxylase 3 interacts with Bcl-2 to regulate doxorubicin-induced apoptosis in H9c2 cells. Biochem Biophys Res Commun. 2010;401:231–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Lee S, Nakamura E, Yang HF, Wei WY, Linggi MS, Sajan MP, Farese RV, Freeman RS, Carter BD, Kaelin WG, Schlisio S. Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell. 2005;. doi: 10.1016/j.ccr.2005.06.015.Google Scholar
  27. 27.
    Sato M, Sakota M, Nakayama K. Human PRP19 interacts with prolylhydroxylase PHD3 and inhibits cell death in hypoxia. Exp Cell Res. 2010;316:2871–82.PubMedCrossRefGoogle Scholar
  28. 28.
    Wang YX, Li ZC, Zhang HB, Jin HF, Sun L, Dong HY, Xu M, Zhao P, Zhang B, Wang J, Pan YL, Liu LL. HIF-1α and HIF-2α correlate with migration and invasion in gastric cancer. Cancer Biol Ther. 2010;10(4):376–82.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Changlei Su
    • 1
  • Kejin Huang
    • 2
  • Lingyu Sun
    • 1
  • Dongdong Yang
    • 1
  • Hongqun Zheng
    • 1
  • Changlu Gao
    • 1
  • Jinxue Tong
    • 1
  • Qifan Zhang
    • 1
  1. 1.Department of Surgical OncologyThe Fourth Hospital of Harbin Medical UniversityHarbinChina
  2. 2.Department of GynecologyThe Third Affiliated Hospital of Harbin Medical UniversityHarbinChina

Personalised recommendations